However, the erythropoietin level by itself cannot make a diagnosis. It needs to be interpreted in the context of the patient’s situation and along with other blood tests. Not only can the test help in anemia, but it is also helpful when the patient has too many red blood cells (polycyt...
Since a previous clinical trial showed that EPO injections once a week for four consecutive weeks is an effective prophylactic treatment for AMS (Heo et al., 2014), we speculate that EPO could be effective for treating at least the subsets of COVID-19 patients that have developed hypoxemia in...
5. An increase in the circulating half-life of EPO in patients which can result in less frequent injections or smaller doses of EPO having to be administered. A prolonged half-life would not only be therapeutically beneficial, but also diminish health care costs in the treatment of chronically...
known as CERA (Constant Erythropoiesis Receptor Activator), which is a polyethyleneglycol derivatised form of EPO. This has been shown to have a longer half-life than EPO, reducing the necessity of frequent injections. A further novel erythropoiesis stimulating...